Recently, MicroPort Medical Sciences Co., Ltd. (hereinafter referred to as "MicroPort Medical") officially announced a series of senior personnel changes. According to the announcement, the company's founder has stepped down from his position as director and related positions, remaining as Chief Scientific Officer. At the same time, the board of directors has appointed a senior veteran within the company as Executive Director and CEO. Currently, the above-mentioned personnel adjustments have fully taken effect.
Trading suspension turmoil
New coach takes office
The underlying reason for this series of high-level personnel turmoil stems from the suspension of trading of MicroPort Medical Systems Co., Ltd.
On September 1st, trading in four Hong Kong-listed companies—MicroPort Medical, MicroPort Robotics, MicroPort CardioFlow, and MicroPort Brain Science—was simultaneously suspended. While the immediate trigger was the failure to disclose their 2026 interim results on schedule, the root cause of the delay pointed to audit and accounting matters related to property leasing arrangements. Therefore, the companies needed more time to assess the lease terms, security deposit arrangements, and the relationship between the lessors and the companies, which stalled the interim reports of all four companies.
However, looking back at the whole year, MicroPort has already carried out a series of personnel adjustments this year.
On April 1, Chang Zhaohua stepped down as CEO, retaining his positions as Chairman of the Board and Chief Scientific Officer. Jonathan W. Chen will serve as rotating CEO, overseeing daily operations on a yearly rotation basis. This adjustment corresponds to establishing a global coordination mechanism, improving strategic execution efficiency, and separating day-to-day operational control from the position of Chairman of the Board.
On August 26, MicroPort CardioFlow, the core platform for structural heart disease intervention in the MicroPort system, also completed a core management team adjustment. Zhang Ruinian resigned as CEO and became president, while Chen Guoming, the former non-executive director, was transferred to executive director.
In the recent announcement of appointments, Chang Zhaohua has further resigned as director and chairman of the board, remaining only as chief scientific officer, while Jonathan W. Chen has been appointed as the new head of MicroPort Medical.
Jonathan W. Chen is a veteran of MicroPort, having joined the company in 2012. He has served as Executive Vice President of International Business and Investor Relations, Director of International Business, and Rotating Co-CEO, and has also served on the boards of several subsidiaries.
In addition, regarding personnel appointments, there is one adjustment to note: MicroPort Medical has clearly defined the division of responsibilities and authority between the board of directors and management, abolished all management structures established without formal board approval, and established a new president's office to assist the CEO, who will also report directly to the board of directors.
Structural imbalance
Addition and subtraction together
The primary challenge facing new CEO Jonathan W. Chen is fulfilling the performance targets set forth during the 2024 funding round. While the 2024-2025 targets have been successfully met, MicroPort Medical now needs to achieve a profit target of $0.9 billion in 2026. However, according to the 2026 interim results forecast, MicroPort Medical still falls short of this goal.
A breakdown of the financial data reveals a divergence between the operational performance and the financial statements. According to the announcement, from an operational perspective, revenue from continuing operations is expected to increase by 12%-14% year-on-year, with overseas business performing particularly well, increasing by approximately 140%. Operating net profit has successfully turned around from a loss of US$13 million in the same period last year to an expected value of no less than US$24 million.
However, the financial statements still project a net loss of no more than $50 million. The shortfall is primarily attributed to non-operating factors such as approximately $43 million in finance costs, a revaluation of the convertible loan's fair value, and exchange rate fluctuations. This means that MicroPort Medical needs a significant profit recovery in the second half of the year to successfully fulfill its performance commitments. Although the company has received an exemption from the financial constraints related to the convertible loan, the final profitability test remains challenging.
As a platform company dubbed "China's Medtronic," MicroPort Medical boasts an extremely large product portfolio. According to data from Yaozhi Medical Devices, MicroPort currently has at least 269 products on the market , and its subsidiaries cover multiple companies including MicroPort Medical, MicroPort CardioFlow, MicroPort Robotics, and MicroPort Electrophysiology, with a broader business scope covering several popular fields such as cardiovascular intervention, orthopedics, aortic and peripheral vascular intervention, neurointervention, and surgical robots.
So, with such a stable product portfolio, why is MicroPort Medical still facing a net loss? Looking at the 2025 annual report data, the core problem lies in the structural imbalance of increasing revenue but not increasing profit . Although MicroPort Medical has many business segments with a wide coverage, there are few profitable segments and many loss-making segments.
As can be seen, the only businesses that truly contribute stable profits are the aortic and peripheral vascular intervention and cardiovascular intervention. While the larger orthopedics and cardiac rhythm management businesses contribute more than 40% of the revenue, they are also the main sources of losses, and their growth potential is limited.
Furthermore, it is worth noting that the surgical robot business, as a strong growth driver, is a potential dark horse, with revenue expected to experience explosive growth in 2025, reaching a growth rate of 114.2%. Although it is still in a loss-making state, driven by the expansion of the domestic surgical robot market and the acceleration of domestic substitution, this segment is expected to grow into the third largest core revenue engine.
Given this fundamental situation, the logic behind MicroPort Medical's asset restructuring in recent years becomes clear: optimizing its balance sheet through a combination of additions and subtractions. For example, in May 2025, it sold part of its shares in MicroPort Robotics, raising HK$458 million. In July 2026, Suzhou MicroPort transferred its 62% stake in Shanghai MicroPort Orthopedics to Tianzhihang in a share swap payment. These actions all point to the same core strategy: divesting or restructuring loss-making and asset-heavy businesses, concentrating resources to solidify its high-margin core business, and building momentum for innovative growth.
Conclusion
Despite the challenges facing MicroPort Medical in 2026, including the suspension of trading in four companies, changes in management, and the divestiture of orthopedic assets, it is still important to objectively acknowledge that its long-established technological barriers and product portfolio remain robust.
Currently, MicroPort Group has 50 products that have successfully entered the innovation channel, a metric that has ranked first in the industry for 11 consecutive years, demonstrating its profound R&D foundation and innovative strength. Furthermore, its financial report also reveals the effectiveness of its globalization strategy, with overseas revenue continuing to climb.
With a new leader at the helm and a restructured governance framework, it remains to be seen whether MicroPort Medical can seize this opportunity to undergo a profound transformation.
Source: https://news.yaozh.com/archive/49268.html